As of close of business last night, Akero Therapeutics Inc’s stock clocked out at $27.54, up 0.62% from its previous closing price of $27.37. In other words, the price has increased by $+0.17 from its previous closing price. On the day, 5144655 shares were traded.
Ratios:
To gain a deeper understanding of AKRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.27 and its Current Ratio is at 29.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on September 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $69.
On August 28, 2023, UBS started tracking the stock assigning a Buy rating and target price of $83.
Morgan Stanley Upgraded its Equal-Weight to Overweight on January 27, 2023, whereas the target price for the stock was revised from $40 to $65.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 13 ’24 when Cheng Andrew sold 1,969 shares for $28.33 per share. The transaction valued at 55,782 led to the insider holds 589,447 shares of the business.
White William Richard sold 724 shares of AKRO for $20,511 on Mar 13 ’24. The Chief Financial Officer now owns 49,630 shares after completing the transaction at $28.33 per share. On Mar 13 ’24, another insider, Yale Catriona, who serves as the Chief Development Officer of the company, sold 723 shares for $28.33 each. As a result, the insider received 20,483 and left with 77,692 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 1.90B and an Enterprise Value of 1.38B.
Stock Price History:
Over the past 52 weeks, AKRO has reached a high of $58.38, while it has fallen to a 52-week low of $11.25. The 50-Day Moving Average of the stock is 23.84, while the 200-Day Moving Average is calculated to be 32.63.
Shares Statistics:
It appears that AKRO traded 1.41M shares on average per day over the past three months and 3.23M shares per day over the past ten days. A total of 68.95M shares are outstanding, with a floating share count of 59.19M. Insiders hold about 14.15% of the company’s shares, while institutions hold 82.85% stake in the company. Shares short for AKRO as of Feb 29, 2024 were 9.4M with a Short Ratio of 6.69, compared to 7.76M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.70% and a Short% of Float of 17.15%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.15, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$1, with high estimates of -$0.8 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$2.89 and -$5.1 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$4.33, with 7 analysts recommending between -$3.36 and -$5.4.
